About Reticulon-4 receptor-like 2
Reticulon-4 receptor-like 2 (RTN4RL2) is a protein
from Homo sapiens identified by UniProt accession
Q86UN3, 420 residues long.
MolForge cross-references it against 0 known binders and
41 disease associations.
Target properties
| Protein name | Reticulon-4 receptor-like 2 |
| UniProt accession | Q86UN3 |
| Gene | RTN4RL2 |
| Organism | Homo sapiens |
| Length | 420 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (41)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.35
- anxiety · score 0.04
- mathematical ability · score 0.04
- neoplasm · score 0.04
- experimental autoimmune encephalomyelitis · score 0.03
- congenital dyserythropoietic anemia type 4 · score 0.03
- Congenital dyserythropoietic anemia type IV · score 0.03
- eosinophil count · score 0.03
- hemoglobin D disease · score 0.03
- hepatorenocardiac degenerative fibrosis · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86UN3-F1 | alphafold | PREDICTED | 79.00 | — |
Amino-acid sequence (420 residues)
MLPGLRRLLQ APASACLLLM LLALPLAAPS CPMLCTCYSS PPTVSCQANN FSSVPLSLPP STQRLFLQNN LIRTLRPGTF GSNLLTLWLF SNNLSTIYPG TFRHLQALEE LDLGDNRHLR SLEPDTFQGL ERLQSLHLYR CQLSSLPGNI FRGLVSLQYL YLQENSLLHL QDDLFADLAN LSHLFLHGNR LRLLTEHVFR GLGSLDRLLL HGNRLQGVHR AAFRGLSRLT ILYLFNNSLA SLPGEALADL PSLEFLRLNA NPWACDCRAR PLWAWFQRAR VSSSDVTCAT PPERQGRDLR ALREADFQAC PPAAPTRPGS RARGNSSSNH LYGVAEAGAP PADPSTLYRD LPAEDSRGRQ GGDAPTEDDY WGGYGGEDQR GEQMCPGAAC QAPPDSRGPA LSAGLPSPLL CLLLLVPHHL
Explore Reticulon-4 receptor-like 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets